Cargando…
M7824: A promising new strategy to combat cancer immune evasion
Autores principales: | Gatti-Mays, Margaret E., Gulley, James L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326736/ https://www.ncbi.nlm.nih.gov/pubmed/30652109 http://dx.doi.org/10.18632/oncoscience.451 |
Ejemplares similares
-
Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
por: Jochems, Caroline, et al.
Publicado: (2017) -
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
por: David, Justin M., et al.
Publicado: (2017) -
Enabling allogeneic therapies: CIRM‐funded strategies for immune tolerance and immune evasion
por: Kadyk, Lisa C., et al.
Publicado: (2020) -
Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
por: Gatti-Mays, Margaret, et al.
Publicado: (2021) -
Nuclear Condensates: New Targets to Combat Parasite Immune Evasion?
por: Luzak, Vanessa
Publicado: (2022)